Relmada Therapeutics (RLMD) Accumulated Expenses (2014 - 2026)
Relmada Therapeutics (RLMD) reported Accumulated Expenses of $594900.0 for Q1 2026, down 85.0% year-over-year from $4.0 million in Q1 2025, and up 11.09% on a QoQ basis from $535500.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 13 years of Accumulated Expenses data on file, last reported at $594900.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 85.0% year-over-year to $594900.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $594900.0 (down 85.0% YoY) and the FY2025 annual result came in at $535500.0, down 91.31% from the prior year.
- Accumulated Expenses improved to $594900.0 in Q1 2026 per RLMD's latest filing, from $535500.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $11.4 million in Q2 2022 and bottomed at $73200.0 in Q2 2023.
- The 5-year median for Accumulated Expenses is $5.5 million (2023), against an average of $4.8 million.
- The widest annual swing landed in 2022, when Accumulated Expenses jumped 14797.21%; it then sank 99.36% in 2023.
- Tracing RLMD's Accumulated Expenses over 5 years: stood at $7.2 million in 2022, then grew by 20.56% to $8.7 million in 2023, then declined by 29.09% to $6.2 million in 2024, then plunged by 91.31% to $535500.0 in 2025, then gained by 11.09% to $594900.0 in 2026.
- Per Business Quant, the three latest RLMD Accumulated Expenses figures stand at $594900.0 (Q1 2026), $535500.0 (Q4 2025), and $532600.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 594,900.00 |
| Dec 31, 2025 | 535,500.00 |
| Sep 30, 2025 | 532,600.00 |
| Jun 30, 2025 | 1.89 Mn |
| Mar 31, 2025 | 3.97 Mn |
| Dec 31, 2024 | 6.16 Mn |
| Sep 30, 2024 | 970,500.00 |
| Jun 30, 2024 | 5.36 Mn |
| Mar 31, 2024 | 7.17 Mn |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 5.57 Mn |
| Jun 30, 2023 | 73,200.00 |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | 7.21 Mn |
| Sep 30, 2022 | 10.35 Mn |
| Jun 30, 2022 | 11.38 Mn |
| Dec 31, 2021 | 3.87 Mn |
| Sep 30, 2021 | 5.54 Mn |
| Jun 30, 2021 | 76,400.00 |
| Mar 31, 2021 | 4.64 Mn |
| Dec 31, 2020 | 4.26 Mn |
| Sep 30, 2020 | 2.66 Mn |
| Jun 30, 2020 | 1.36 Mn |
| Mar 31, 2020 | 1.16 Mn |
| Dec 31, 2019 | 824,900.00 |
| Sep 30, 2019 | 1.01 Mn |
| Jun 30, 2019 | 1.32 Mn |
| Mar 31, 2019 | 1.02 Mn |
| Dec 31, 2018 | 1.39 Mn |
| Sep 30, 2018 | 966,161.00 |
| Jun 30, 2018 | 659,455.00 |
| Mar 31, 2018 | 458,584.00 |
| Dec 31, 2017 | 494,096.00 |
| Sep 30, 2017 | 407,307.00 |
| Jun 30, 2017 | 394,558.00 |
| Mar 31, 2017 | 586,442.00 |
| Dec 31, 2016 | 472,480.00 |
| Sep 30, 2016 | 404,886.00 |
| Jun 30, 2016 | 634,853.00 |
| Mar 31, 2016 | 1.05 Mn |
| Dec 31, 2015 | 1.56 Mn |
| Sep 30, 2015 | 614,531.00 |
| Jun 30, 2015 | 482,267.00 |
| Mar 31, 2015 | 398,485.00 |
| Dec 31, 2014 | 521,684.00 |
| Sep 30, 2014 | 879,497.00 |
| Jun 30, 2014 | 382,023.00 |